Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Moodys
Express Scripts
Johnson and Johnson
Baxter

Last Updated: May 26, 2022

Investigational Drug Information for ODM-201


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for ODM-201?

ODM-201 is an investigational drug.

There have been 47 clinical trials for ODM-201. The most recent clinical trial was a Phase 3 trial, which was initiated on May 5th 2017.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Parkinson Disease, and Motor Neuron Disease. The leading clinical trial sponsors are Orion Corporation, Orion Pharma, Bayer, and National Cancer Institute (NCI).

There are twenty-one US patents protecting this investigational drug and three hundred and seventeen international patents.

Recent Clinical Trials for ODM-201
TitleSponsorPhase
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk ScoreNational Cancer Institute (NCI)Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk ScoreNRG OncologyPhase 3
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate CancerBayerPhase 2

See all ODM-201 clinical trials

Clinical Trial Summary for ODM-201

Top disease conditions for ODM-201
Top clinical trial sponsors for ODM-201

See all ODM-201 clinical trials

US Patents for ODM-201

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ODM-201 See Plans and Pricing Carboxamide derivative and its diastereomers in stable crystalline form Orlon Corporation (Espoo, FI) See Plans and Pricing
ODM-201 See Plans and Pricing Androgen receptor modulating compounds ORION CORPORATION (Espoo, FI) See Plans and Pricing
ODM-201 See Plans and Pricing Process for the preparation of androgen receptor antagonists and intermediates thereof Orion Corporation (Espoo, FI) See Plans and Pricing
ODM-201 See Plans and Pricing Compositions and methods for treatment of prostate cancer California Institute of Technology (Pasadena, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ODM-201

Drugname Country Document Number Estimated Expiration Related US Patent
ODM-201 European Patent Office EP3250554 2035-01-30 See Plans and Pricing
ODM-201 Japan JP2018503662 2035-01-30 See Plans and Pricing
ODM-201 Japan JP2021020935 2035-01-30 See Plans and Pricing
ODM-201 World Intellectual Property Organization (WIPO) WO2016120530 2035-01-30 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Moodys
Express Scripts
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.